ARM makes little difference to cataract surgery outcomes

Article

Patients with age-related maculopathy (ARM) undergoing cataract surgery can expect favourable visual and quality of life outcomes one to three years following surgery, according to the results of a study published in the March issue of Eye.

Patients with age-related maculopathy (ARM) undergoing cataract surgery can expect favourable visual and quality of life outcomes one to three years following surgery, according to the results of a study published in the March issue of Eye.

Jie Jin Wang and colleagues from the University of Sydney and the Westmead Hospital, New South Wales, Australia re-examined patients with and without ARM who had undergone cataract surgery between 2001 and 2003. They tested visual acuity (VA) and assessed visual and health-related quality of life (HRQoL) using standardized questionnaires (VF-14, SF-12). Preoperative co-morbidity data was collected from medical records. Poor surgical outcomes (VA< 6/12; no improvement in VA; lowest quintile of VF-14, SF-12 scores) were compared in subjects with and without ARM.

A total of 454 patients were followed up for a mean period of 2.8 years. Similar numbers of patients in the ARM and non-ARM groups had VA< 6/12, equating to 80.2% and 88.8%, respectively. Preoperative early ARM was associated with a slightly lower mean VF-14 score. Increasing age and preoperative ocular co-morbidities were associated with all poor outcomes measured.

The results of this study suggest that patients with ARM who have undergone cataract surgery can expect reasonable outcomes over three years.

Recent Videos
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Related Content
© 2025 MJH Life Sciences

All rights reserved.